← All trials
NCT04932213
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 7, 2021
- Primary completion
- Nov 7, 2021
- Completion date
- Nov 7, 2021
- First posted
- Jun 21, 2021
- Last posted
- Nov 19, 2021
- Enrollment
- 98
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TehranLead sponsor
- University of TehranReponsible party - principal investigator
- Semnan University of Medical SciencesOverall official - principal investigator
- Semnan University of Medical SciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.